Lv56
815 积分 2021-06-04 加入
Effect of nerandomilast on survival in patients with pulmonary fibrosis
9小时前
已完结
Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
2天前
已完结
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
8天前
已完结
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
8天前
已完结
Disease-Modifying Therapies in Multiple Sclerosis
8天前
已完结
Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod
9天前
已完结
Prevalence of multiple sclerosis and treatment utilization in a large, highly diverse population
9天前
已完结
Prevalence of multiple sclerosis and disease-modifying therapy use in older adults in the United States, 2011–2021
9天前
已完结
Misdiagnosis and underdiagnosis of multiple sclerosis: A systematic review and meta-analysis
9天前
已完结
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria
9天前
已完结
皖公网安备34019202002308
